NEW YORK--(BUSINESS WIRE)--
Levi & Korsinsky announces it has commenced an investigation of Arrowhead Pharmaceuticals, Inc. (“Arrowhead Pharmaceuticals” or the “Company”) (NASDAQ:ARWR) concerning possible violations of federal securities laws by certain officers and directors.
On November 8, 2016, after the close of the market, Arrowhead Pharmaceuticals announced that the United States Food & Drug Administration had decided to place a clinical hold on the Company’s Heparc-2004 clinical study of ARC-520. According to the company, the hold stems from deaths at the highest dose of an ongoing non-human primate toxicology study; these deaths are currently under investigation. Following this news, shares of Arrowhead Pharmaceuticals shares fell from a close of $6.11 per share to a close of $4.45 per share on November 9, 2016. To obtain additional information about the investigation, go to:
http://zlk.9nl.com/arrowhead-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30
Broad Street - 24th Floor
New York, NY 10004
Tel: (212)
363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161109005901/en/
